Kidney transplant — maintenance immunosuppression
transplant IS · Renal / Electrolyte
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Lifelong maintenance immunosuppression (typically a calcineurin inhibitor, antimetabolite and tapering steroid) prevents rejection while balancing infection and malignancy risk. Drug levels, graft function and complications require careful ongoing monitoring.
Red flags
- Rising creatinine (rejection, CNI toxicity, BK nephropathy)
- Fever/neutropenia or opportunistic infection
- New heavy proteinuria (recurrent/de novo GN)
- Very high or sub-therapeutic CNI levels
- New lymphadenopathy/mass (PTLD)
Assessment
Differential diagnosis
- Stable graft function
- Acute rejection (if function declining)
- Calcineurin inhibitor nephrotoxicity
- BK virus nephropathy
- Recurrent/de novo glomerular disease
- Infection or dehydration causing dysfunction
Investigations
- Tacrolimus/ciclosporin trough levels
- Creatinine/eGFR trend and urine ACR/PCR
- FBC (antimetabolite marrow suppression)
- BK and CMV viral loads (surveillance)
- Fasting glucose/HbA1c, lipids (metabolic effects)
- Donor-specific antibodies if dysfunction/rejection suspected; biopsy if needed
Management
- Confirm the maintenance regimen (commonly tacrolimus + mycophenolate + prednisolone) and target CNI trough by time post-transplant
- Monitor tacrolimus troughs and titrate to target (higher early, lower long-term) while watching renal function
- Monitor graft function (creatinine, ACR) and investigate any rise promptly (rejection, CNI toxicity, BK, obstruction, dehydration)
- Perform protocol viral surveillance (BK, CMV) and reduce immunosuppression for BK viraemia/nephropathy
- Give infection prophylaxis early post-transplant (co-trimoxazole for PCP, valganciclovir for CMV per risk, antifungal as indicated)
- Screen for and manage metabolic complications: post-transplant diabetes, hypertension, dyslipidaemia
- Counsel on skin cancer prevention and arrange dermatological/malignancy surveillance
- Avoid drug interactions that alter CNI levels (azoles, macrolides, diltiazem, grapefruit)
- Manage CNI nephrotoxicity by dose adjustment or conversion (e.g. to belatacept/mTOR inhibitor) where appropriate
- Reinforce adherence — non-adherence is a major cause of late graft loss
- Vaccinate (inactivated vaccines; avoid live vaccines) and keep screening up to date
- Review immunosuppression, levels and complications at regular transplant clinics
Drugs & doses
Tacrolimus 0.05-0.1 mg/kg/day PO in two divided doses, titrated to trough (early target ~5-10 ng/mL, later ~4-8 ng/mL)
Mycophenolate mofetil 500-1000 mg PO twice daily (or mycophenolic acid equivalent)
Prednisolone 5-10 mg PO daily (maintenance, if not steroid-sparing)
Co-trimoxazole 480 mg PO daily (PCP prophylaxis)
Valganciclovir 900 mg PO daily, renally adjusted (CMV prophylaxis for at-risk)
Ciclosporin 3-5 mg/kg/day PO in two doses (alternative CNI), titrated to level
Disposition
Transplant nephrology clinic for lifelong follow-up. Urgent transplant centre contact for graft dysfunction, fever or suspected rejection. Biopsy for unexplained decline.
Complications & pitfalls
- Acute and chronic rejection
- CNI nephrotoxicity
- Opportunistic infection (CMV, BK, PCP)
- Post-transplant diabetes, hypertension, dyslipidaemia
- Malignancy (skin cancers, PTLD)
- Marrow suppression from antimetabolites
Exam pearls
- Any unexplained creatinine rise in a transplant needs prompt work-up for rejection, CNI toxicity or BK
- Watch for CYP3A interactions (azoles, diltiazem, macrolides) that spike tacrolimus levels
- Reduce immunosuppression, do not add antivirals, for BK nephropathy
- Non-adherence is a leading cause of late graft loss
- Avoid live vaccines in immunosuppressed recipients
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.